<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01617564</url>
  </required_header>
  <id_info>
    <org_study_id>W2010IM</org_study_id>
    <nct_id>NCT01617564</nct_id>
  </id_info>
  <brief_title>Paracervical Block During II-trimester Abortion</brief_title>
  <official_title>Paracervical Block (PCB) During II-trimester Abortion- A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kristina Gemzell Danielsson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Paracervical blockage can reduce severe pain during second trimester induced medical
      abortion.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain score</measure>
    <time_frame>at 24 hours</time_frame>
    <description>Pain indicated on VAS at specific time intervals during the induction to expulsion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>after 24h from induction</time_frame>
    <description>Number of complete abortions within 24h without the need for surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to abortion</measure>
    <time_frame>at 24hours</time_frame>
    <description>Time from induction (first dose of misoprostol) to expulsion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>at 6 to 8 weeks</time_frame>
    <description>AEs reported during the time period from mifepristone (Day 1)until follow up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Second Trimester Medical Abortion</condition>
  <arm_group>
    <arm_group_label>Bupivacain</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Chloride</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bipuvacain</intervention_name>
    <description>PCB with 20ml bupivakain or sodium cloride 9mg/ml will be administered one hour following misorpostol administration (first dose).</description>
    <arm_group_label>Bupivacain</arm_group_label>
    <other_name>(Marcain® 2,5mg/ml)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NaCl</intervention_name>
    <description>PCB with 20ml sodium chloride (9mg/ml) inactive (sham) comparator</description>
    <arm_group_label>Sodium Chloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women who request second trimester medical abortion (13-22 weeks gestation according
             to ultrasound)

          -  18 years of age or older

          -  able to understand and communicate in Swedish

          -  able to understand the study related information and willing to give her

          -  informed consent to participation in the study

        Exclusion Criteria:

          -  Known allergy to bupivakain or related substances
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristina Gemzell Danielsson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept of Obstetrics and Gynecology, Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>SE17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Södersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2012</study_first_submitted>
  <study_first_submitted_qc>June 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2012</study_first_posted>
  <last_update_submitted>May 15, 2015</last_update_submitted>
  <last_update_submitted_qc>May 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Kristina Gemzell Danielsson</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>medical abortion</keyword>
  <keyword>second trimester</keyword>
  <keyword>para cervical blockage</keyword>
  <keyword>pain management</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

